Home     About Us     Team     Products     News     Contact     FAQ     Account

Drugs & Biologicals

Arzerra (ofatumumab)

Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis ...Wikipedia

 

 

Manufacturer's Website: Arzerra                                                                                                                      Average retail cost: $580/vial

 

 

 

Search Terms: Arzerra, ofatumumab, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis, relapsing remitting multiple sclerosis

Copyright 2006-2022 Automated Clinical Guidelines, LLC. All rights reserved.